{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T14:57:56Z","timestamp":1792508276991,"version":"4.5.0"},"reference-count":28,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019832","name":"Gal\u00e1pagos","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019832","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019211","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019211","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Arthritis &amp; Rheumatology"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Our objective was to assess the incidence of major adverse cardiovascular events (MACEs) in patients with rheumatoid arthritis (RA) treated with JAK inhibitors (JAKi), tumor necrosis factor inhibitors (TNFi), or biologic disease\u2010modifying antirheumatic drugs with other modes of action (bDMARD\u2010OMA) in a multicountry, real\u2010world population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients with RA from 15 registries in the JAK\u2010pot collaboration were included. MACE incidence was analyzed using two approaches: a within\u2010registry analysis aggregating country\u2010specific estimates from registers with &gt;25 incident MACEs through meta\u2010analysis and an individual\u2010level data combined analysis. We used adjusted linear mixed Poisson regression to obtain incidence rate ratios (IRRs) of MACEs between treatment groups, accounting for multiple treatment courses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The study included 73,008 treatment courses (16,417 JAKi, 35,373 TNFi, and 21,218 bDMARD\u2010OMA) and 828 incident MACEs among 51,233 patients. Median follow\u2010up time was 1.3 years, with most of the follow\u2010up concentrated in the first two years of treatment. Incidence rates were 7.0, 7.6, and 11.8 per 1,000 person\u2010years for JAKi, TNFi, and bDMARD\u2010OMA, respectively. Compared to TNFi, JAKi (within\u2010registry adjusted IRR 0.89, 95% confidence interval [CI] 0.63\u20131.25) had similar incidence rates of MACEs and bDMARD\u2010OMA had higher rates (within\u2010registry adjusted IRR 1.35, 95% CI 1.10\u20131.66). Combined analysis showed similar results.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Observational data from the JAK\u2010pot collaboration show no evidence of an increase in cardiovascular events during the first two years of use with JAKi compared to TNFi in the general RA population.<\/jats:p><\/jats:sec>","DOI":"10.1002\/art.43188","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T03:33:06Z","timestamp":1744687986000},"page":"1194-1204","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Incidence of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis Treated With <scp>JAK<\/scp> Inhibitors Compared With Biologic Disease\u2010Modifying Antirheumatic Drugs: Data From an International Collaboration of Registries"],"prefix":"10.1002","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2854-3632","authenticated-orcid":false,"given":"Romain","family":"Aymon","sequence":"first","affiliation":[{"name":"Department of Rheumatology Geneva University Hospital  Geneva Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Mongin","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Geneva University Hospital  Geneva Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Guemara","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Geneva University Hospital  Geneva Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zubeyir","family":"Salis","sequence":"additional","affiliation":[{"name":"University of Montpellier and Physiology and Experimental Medicine of the Heart and Muscles  Montpellier France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Askling","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Division, Department of Medicine Solna Karolinska Institutet  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Choquette","sequence":"additional","affiliation":[{"name":"Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9al, Institut de Recherche en Rhumatologie, Montr\u00e9al  Qu\u00e9bec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catalin","family":"Codreanu","sequence":"additional","affiliation":[{"name":"University of Medicine, Center of Rheumatic Diseases  Bucharest Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Di Giuseppe","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Division, Department of Medicine Solna Karolinska Institutet  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irini","family":"Flouri","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology University Hospital of Heraklion  Crete Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doreen","family":"Huschek","sequence":"additional","affiliation":[{"name":"Deutsches Rheuma\u2010Forschungszentrum Programme Area Epidemiology  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimme L.","family":"Hyrich","sequence":"additional","affiliation":[{"name":"National Institute for Health and Care Research Manchester Biomedical Research Centre Manchester University NHS Trust  Manchester United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0474-5344","authenticated-orcid":false,"given":"Florenzo","family":"Iannone","sequence":"additional","affiliation":[{"name":"Department of Precision and Regenerative Medicine and Ionian Area Rheumatology Unit University of Bari  Bari Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8441-3093","authenticated-orcid":false,"given":"Tore K.","family":"Kvien","sequence":"additional","affiliation":[{"name":"Diakonhjemmet Hospital Center for Treatment of Rheumatic and Musculoskeletal Diseases  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burkhard F.","family":"Leeb","sequence":"additional","affiliation":[{"name":"BioReg  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Nordstr\u00f6m","sequence":"additional","affiliation":[{"name":"Departments of Medicine and Rheumatology Helsinki University Hospital, The National Register of Biological Medicines  Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Otero\u2010Varela","sequence":"additional","affiliation":[{"name":"Research Unit Spanish Society of Rheumatology  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1952-8422","authenticated-orcid":false,"given":"Karel","family":"Pavelka","sequence":"additional","affiliation":[{"name":"Institute of Rheumatology  Prague Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Pombo\u2010Suarez","sequence":"additional","affiliation":[{"name":"NOVA Medical School Universidade Nova de Lisaboa  Lisbon Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Rodrigues","sequence":"additional","affiliation":[{"name":"NOVA Medical School, Universidade Nova de Lisaboa and Reuma.pt, Sociedade Portuguesa de Reumatologia  Lisbon Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziga","family":"Rotar","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University Medical Centre Ljubljana &amp; Faculty of Medicine University of Ljubljana  Ljubljana Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prodromos","family":"Sidiropoulos","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology University Hospital of Heraklion  Crete Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5442-902X","authenticated-orcid":false,"given":"Sella A.","family":"Provan","sequence":"additional","affiliation":[{"name":"Diakonhjemmet Hospital Center for Treatment of Rheumatic and Musculoskeletal Diseases  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Strangfeld","sequence":"additional","affiliation":[{"name":"Deutsches Rheuma\u2010Forschungszentrum Programme Area Epidemiology and Charit\u00e9 \u2013 Universit\u00e4tsmedizin  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trokovic","family":"Nina","sequence":"additional","affiliation":[{"name":"Departments of Medicine and Rheumatology Helsinki University Hospital, The National Register of Biological Medicines  Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Zavada","sequence":"additional","affiliation":[{"name":"Institute of Rheumatology  Prague Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0377-1575","authenticated-orcid":false,"given":"Lianne","family":"Kearsley\u2010Fleet","sequence":"additional","affiliation":[{"name":"Centre for Epidemiology Versus Arthritis, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology Medicine and Health The University of Manchester, Manchester Academic Health Science Centre  Manchester United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine S.","family":"Courvoisier","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Geneva University Hospital  Geneva Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Finckh","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Geneva University Hospital and Geneva Center for Inflammation Research University of Geneva  Geneva Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Lauper","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Geneva University Hospital  Geneva Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,5,21]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(20)30221-6"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24092"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-017-0632-2"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k1036"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209784"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2011.06.054"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109927"},{"key":"e_1_2_7_9_1","unstructured":"European Medicine Agency 2021 Xeljanz (tofacitinib): initial clinical trial results of increased risk of major adverse cardiovascular events and malignancies (excluding NMSC) with use of tofacitinib relative to TNF\u2014 alpha inhibitors"},{"key":"e_1_2_7_10_1","unstructured":"US Food and Drug Administration FDA 2021 Initial safety trial results find increased risk of serious heart\u2010related problems and cancer with arthritis and ulcerative colitis medicine Xeljanz Xeljanz XR (tofacitinib)"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003630"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead531"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003489"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224670"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223356"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-222586"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222835"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22456"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.11.008"},{"key":"e_1_2_7_20_1","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2023"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v045.i03"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.5114\/aoms.2017.71371"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206737"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214259"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206879"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222824"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221915"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.4178\/epih.e2023045"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0175605"}],"container-title":["Arthritis &amp; Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.43188","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T11:42:25Z","timestamp":1759923745000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/art.43188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,21]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1002\/art.43188"],"URL":"https:\/\/doi.org\/10.1002\/art.43188","archive":["Portico"],"relation":{},"ISSN":["2326-5191","2326-5205"],"issn-type":[{"value":"2326-5191","type":"print"},{"value":"2326-5205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,21]]},"assertion":[{"value":"2024-11-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}